Description
Orforglipron is the first orally available small-molecule agonist of the GLP-1 receptor that has successfully completed Phase 3 studies. Unlike classical oral peptide variants, Orforglipron is not a peptide but a small chemical compound. This eliminates the absorption problems peptides have in the gastrointestinal tract.
Per study reports Orforglipron activates the GLP-1 receptor with similar selectivity and potency as Semaglutide, but with two decisive advantages: first, oral bioavailability without absorption enhancers; second, no restrictions on fasting intake or water limits. Orforglipron is simply swallowed daily, with or without food.
The substance was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. In the landmark ATTAIN-1 study (Phase 3, 2025) subjects under 36mg Orforglipron achieved 11.2% weight loss over 72 weeks - comparable with Wegovy, but as a convenient oral tablet.
In the parallel ACHIEVE study in type-2 diabetes, Orforglipron significantly lowered glycated hemoglobin (HbA1c) over 40 weeks. Global approval applications were submitted at the end of 2025, market approval expected for 2026.
Pharmacokinetically orally bioavailable with excellent bioavailability. Half-life allows once-daily dosing. Safety profile consistent with the GLP-1 class: gastrointestinal effects at start, subside with titration.
You can order Orforglipron as oral tablets in one bottle with 6mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
As an oral small-molecule agonist, Orforglipron activates the same GLP-1 receptor as the peptide compounds, so the documented safety profile is correspondingly consistent with the GLP-1 class and shaped by gastrointestinal effects.
Observed in studies and user reports:
- Gastrointestinal effects: nausea, vomiting, diarrhea and constipation are the most commonly documented observations, particularly at the start, and subside with titration in the Phase 3 studies. Slow titration reduces the incidence.
- Appetite and fluids: the reduced appetite can lead to decreased food and fluid intake, and the literature describes an elevated risk of dehydration.
- Muscle mass and gallbladder: weight loss involves a portion of muscle mass alongside fat mass, and gallbladder issues during rapid weight loss are documented for the GLP-1 class.
- Class signals: as with other GLP-1 agonists, the literature discusses rare safety signals such as pancreatitis.
- Limited long-term data: Orforglipron has completed the Phase 3 studies but is a very new compound, and data beyond the study periods are lacking.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) - NEJM 2025: Phase 3 gold-standard obesity study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1) - NEJM 2025, Rosenstock et al: Phase 3 trial, all three doses significantly lowered HbA1c over 40 weeks versus placebo.
- Orforglipron for treatment of obesity in people with type 2 diabetes (ATTAIN-2) - Lancet 2025: Co-morbidity obesity + diabetes study.
